Prospective Cohort Study of Palbociclib for Postmenopausal Metastatic Breast Cancer

Not Applicable

• Conditions: postmenopausal patients with unresectable and metastatic hormone receptor-positive breast cancer,

• Registration Number: JPRN-UMIN000035863
• Lead Sponsor: CSPOR-BC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-02-20
• Study Completion: 2024-01-31
• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 700

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who is not adopt endocrine therapy.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
progression-free survival (PFS) in each treatment line.

Secondary Outcome Measures

Name	Time	Method
1) overall survival, 2) clinical benefit rate (CBR) 3) AEs 4) patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) 5) PFS 6) CBR with the next treatment 7) AEs caused by the subsequent treatment, 8) PRO-CTCAE with the subsequent treatment 9) reasons for selecting the treatment.